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T cell/histiocyte-rich large B cell lymphoma (THRLBCL) is predominantly a nodal disease, with extranodal involvement, such
as bone marrow, spleen, and liver. However, primary THRLBCL has never been reported in the thymus in the English literature.
Here we report a case of THRLBCL presenting as mediastinal mass and lymphadenopathy. Based on the frozen section diagnosis
of “thymoma,” a 12 cm mass was excised. A year later she developed multiple enlarged lymph nodes and pulmonary nodules.
Consultant review of the excised mediastinal mass showed scattered large atypical cells that were CD20+ and PAX-5+ and negative
for pan-cytokeratin, AE1, and AE3, compatible with THRLBCL and excluding thymoma. The excised lymph nodes were replaced by
diffuse infiltrate of small CD3+ lymphocytes and histiocytes with intermingled large CD20+ B lymphoma cells scattered throughout
the section. A diagnosis of THRLBCL was made in lymph node, similar to previous thymic lesion. A clonal rearrangement of
immunoglobulin heavy chain (IGH) gene was detected, further supporting the diagnosis. This is the first reported case of THRLBCL
in thymus. Correct recognition of this entity is critical, because of the difference in therapeutic impact on these patients.

1. Introduction
The thymus is the primary site of T cell development; however, both T and B cell lymphomas can arise from thymus.
Hodgkin’s lymphoma, primary mediastinal (thymic) large B
cell lymphoma [PMBL, a subtype of diffuse large B cell lymphoma (DLBCL)], and lymphoblastic lymphoma are the most
common thymic lymphoid neoplasms. T cell/histiocyterich large B cell lymphoma (THRLBCL) is a morphologic
variant of DLBCL characterized by fewer than 10% large
neoplastic cells amid a prominent inflammatory infiltrate,
the majority of which are small polyclonal T cells with or
without the presence of histiocytes, and it has never been
reported in the thymus in the English literature to date.
THRLBCL is predominantly a nodal disease, but extranodal
sites, such as bone marrow, liver, and spleen, can be involved
[1]. Herein we report the first case of THRLBCL arising
from thymus. The present patient also had a history of
Sjögren’s syndrome (SS), a chronic autoimmune epithelitis
characterized by lymphocytic infiltration of exocrine glands

together with polyclonal B cell activation [2, 3]. Patients
with SS have increased risk for lymphoma and the prevalence of non-Hodgkin lymphoma (NHL) in SS is about
5% [4]. Various subtypes of NHL have been described in
SS, with marginal zone lymphoma of mucosa-associated
lymphoid tissue (MALT lymphoma) being the most common
one. However, THRLBCL is extremely rare in SS patients
with only one case reported in the parotid gland so far
[5].

2. Case Report
The patient was a 52-year-old African American woman
who had a long-standing history (>10 years) of SS and had
been treated with corticosteroid. She was admitted to a
regional medical center for a sudden onset of chest pain. CT
scan showed a large anterior mediastinal mass and several
enlarged mediastinal lymph nodes (Figures 1(a) and 1(b));
liver and spleen were unremarkable. Her HIV serology was
negative. During the surgery, a mass was identified extending
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Figure 1: Chest computed tomography (CT) scan. Before resection of the mediastinal mass, chest CT scan showed a 12 cm anterior mediastinal
mass (a) and lymph nodes (b). A year after the surgery, CT scan revealed multiple enlarged lymph nodes, such as cervical lymph nodes (c),
paratracheal lymph node (d), and pulmonary nodules (e). Arrows indicated the lesions.

from the right side of midline all the way over into the left
chest into the hilum of the left lung, adhering to the pericardium as well as to the pleural surface on the left side and
involving the phrenic nerve. The intraoperative pathological
diagnosis of the mass was reported as “thymoma” and the
mass and mediastinal lymph nodes were then excised and
submitted for pathology. On gross examination, a large (12 ×
9.5 × 7 cm, 237 grams), irregular, pink to dark red mass had
pink-tan, lobular appearing cut surface separated by bands of
yellow-tan tissue. Areas of ischemia or necrosis were present.
Multiple lymph nodes (0.5–1.3 cm) were noted at one end of
the mass. The permanent sections of the mass and lymph
nodes were reported as “thymoma, lymphocyte predominant
type; benign reactive lymph nodes.” The patient’s postoperative course was uneventful. However, a year later, a followup CT showed multiple enlarged lymph nodes throughout
the chest and upper abdomen, multiple new noncalcified
pulmonary nodules, and bilateral pulmonary dense consolidation (Figures 1(c)–1(e)). The patient also reported night
sweats, low grade fever, flu-like symptoms, green sputum

production, 14 lb weight loss, and some shortness of breath
with exertion. Biopsies of multiple lymph nodes (right
cervical and bilateral lower paratracheal) were performed.
Pathology material from previous mediastinal mass resection
and current lymph node biopsy were sent to our medical
center for review and consultation.
Consultative review of the mediastinal mass sections
showed thymic tissue rimmed by collagenous fibrous capsule
(Figure 2(a)). Hyperplastic lymphoid infiltrate was present
consisting of diffuse CD3+ T cells (predominantly), nodular
areas of CD20+ B cells, and distinct, well formed germinal
centers (Figure 2(b)). Preserved follicular dendritic network
(CD21+) was present in the germinal centers. These features
are consistent with thymic lymphoid follicular hyperplasia.
This diffuse lymphoid hyperplasia resulted in an indistinct
border between thymic cortex and medulla, a distorted and
compressed epithelial network (highlighted by immunostains
for AE1 and AE3; Figure 2(c)), and markedly decreased
number of Hassall’s corpuscles. Scattered large atypical cells
were present in the interfollicular area.
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Figure 2: Mediastinal mass, thymic THRLBCL. (a) Thymic tissue rimmed by collagenous fibrous capsule (H&E, 2x). (b) Nodular areas of B
cells (CD20, 4x). (c) Distorted and compressed epithelial network (AE1 and AE3, 2x). (d) Large lymphoid cells were scattered singly among
small lymphocytes (H&E, 100x). (e) The dispersed large B cell lymphoma cells and some small B lymphocytes (CD20, 40x). (f) Numerous T
lymphocytes in the background (CD3, 40x).

Furthermore, focally effaced areas contained large atypical lymphoid cells in a background of small lymphoid cells
(Figures 2(d) and 2(f)). The large atypical cells had irregular
nuclei, vesicular chromatin, and one or more nucleoli and
were CD20+ (Figure 2(e)), PAX5+, and CD30+ (subsets only)
but were negative for CD15 and EBER (in situ hybridization).
A proliferation fraction of 15–30% by Ki-67 was identified
in the areas with large atypical B lymphocytes. Patchy areas
of necrosis were also present. No prominent histiocytic
proliferation was identified in the thymic mass. Epithelial
proliferation, as seen in thymoma, was absent, which was
confirmed by several negative immunostains for different
keratin markers, including pan-cytokeratin, AE1, and AE3.
The histomorphologic features and the immunophenotype
resulted in a diagnosis of thymic THRLBCL.
In addition, the mediastinal lymph node from previous
mediastinal mass resection and the bilateral lower paratracheal and right cervical lymph nodes from recent biopsy
showed similar morphology as follows: mostly or entirely
effaced lymph node architecture by predominantly small
CD3+ lymphocytes, with residual nodular CD20+ B lymphoid areas and CD21+ germinal centers present in some
sections (Figures 3(a), 3(c), and 3(d)). Interspersed large
atypical lymphocytes (Figure 3(b)) were present in the background of T lymphocytic (CD3+) and histiocytic (CD68+,

CD163+) proliferation (Figures 3(d) and 3(e)). The large
atypical lymphoid cells were CD20+, PAX-5+, MUM-1+, and
CD30+ (subsets only) but showed no reactivity to CD15, S100, or EBER (in situ hybridization) (Figure 3(f)). Immunostain for Ki-67 revealed a proliferation fraction of 30–40%
among large atypical lymphoid cells. No epithelial cells were
identified by immunostains for pan-cytokeratin, AE1, and
AE3. No acid fast bacilli or fungal organisms were identified
by ZN and GMS stains. The histopathological changes of the
lymph nodes were consistent with THRLBCL. Polymerase
chain reaction (PCR) detected a clonal rearrangement of
immunoglobulin heavy (IGH) chain (Figure 4(c)), further
supporting the B cell neoplastic process.

3. Discussion
Malignant lymphoma is the second most common primary
anterior mediastinal tumors in adults [6]. The thymus,
located in the anterior mediastinum, is the primary anatomic
site of T cell development. Therefore, it is not surprising that
many lymphoid malignant neoplasms arising within the
thymus are T cell neoplasms, mostly T cell lymphoblastic
lymphoma. However, malignant neoplasms of B cell lineage,
such as Hodgkin’s lymphoma and PMBL, are not uncommon in thymus [7]. Several studies have documented the
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Figure 3: THRLBCL in the right cervical lymph node. (a) The lymph node structure was almost entirely effaced by diffuse small lymphocytes
with some residual follicles present (H&E, 4x). (b) Large atypical cells were surrounded by small lymphocytes and histiocytes (H&E, 40x). (c)
CD20 immunostain showed the residual follicles (4x). (d) The diffuse small lymphocytes were CD3+ T lymphocytes (4x). (e) Many histiocytes
were stained by CD163 (4x). (f) Immunohistochemistry for CD20 highlighted large B lymphoma cells (40x).

existence of a minor population of B cells in the thymus of
both humans and mice [8]. These cells are located in the
medulla, primarily around Hassall corpuscles, constituting
approximately one-third of all medullary cells and may play
a role in thymic negative selection. Hodgkin’s lymphoma,
PMBL, and lymphoblastic lymphoma are the most common
thymic lymphoid neoplasms.
In the present patient, the large atypical cell scattered in
the background of small lymphocytes led to a list of histological differential diagnosis: THRLBCL, Hodgkin’s lymphoma,

and thymoma of lymphocytes predominant type. THRLBCL
is a variant of DLBCL and accounts for <10% of all DLBCL.
THRLBCL is associated with a prominent component of
reactive T cells, which may be related to interleukin-4
production by the lymphoma cells [9]. Previous studies show
evidence that IL-4 may play a role in the proliferation of
T cells and/or the suppressor of B cell growth (although
it is still subject to investigation). The presence of IL-4 in
THRLBCLs but not in the other DLBCLs and reactive lymph
nodes suggests that IL-4 may be a major factor involved in
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Figure 4: B cell clonality detection by PCR (IGH-PCR). A clonal IGH gene rearrangement was identified in framework 3 region (c), but not
in framework 1 (a) or 2 (b) region.

the pathology of THRLBCLs and it is an important factor
for the differential diagnosis of this entity. THRLBCL mainly
affects middle-aged man and is predominantly a nodal
disease, but extranodal sites, such as bone marrow, liver, and
spleen, can be involved [1]. However, no cases of THRLBCL have been reported in the thymus. THRLBCL usually
presents with higher stage of disease and more commonly
involves bone marrow and spleen compared to conventional
DLBCL. Histologically, large lymphoid cells are scattered
singly among small lymphocytes (reactive CD3+CD5+CD8+
T cells). The relative low number of neoplastic cells may
be partially explained by tumor cell apoptosis mediated by
cytotoxic CD8+ T cells [10]. The large cells are pleomorphic
with irregular nuclei, expressing pan-B markers and BCL6,
and are negative for CD15, CD30, CD5, CD10, and EBV. BCL2
and EMA can be variable positive [1].
The histology of THRLBCL can mimic Hodgkin’s lymphoma, such as lymphocyte-rich type of classical Hodgkin’s
lymphoma (LRCHL) and nodular lymphocyte predominant Hodgkin’s lymphoma (NLPHL). In LRCHL, the ReedSternberg cells are usually positive for CD15, CD30, and EBV
but negative for pan-B markers or heterogenous staining if
positive. The present case was positive for B markers (CD20
and PAX-5) but negative for CD15 and EBV, though CD30
was weakly and focally positive, which mitigated against the
diagnosis of LRCHL. NLPHL usually shows nodules containing numerous small lymphocytes and a variable number
of variant Hodgkin’s cells (popcorn cells) which are usually
positive for CD45 and CD20 but negative for CD15 and CD30.
However, the surrounding small lymphocytes in NLPHL are
usually a mixture of B cells (predominately) and T cells
(though rich T cells can be seen in late stage of NLPHL), and
CD57+ or PD-1+ T cells rosette around the large neoplastic
B cells [11]. In the present case, the small lymphocytes in
the background were predominantly CD3+ T cells with no T
cells rosette around the large neoplastic cells, making NLPHL
unlikely. Another important differential diagnosis for the
present case is thymoma of lymphocyte predominant type.
Thymoma is characterized by neoplastic epithelial proliferation. Even if lymphocytes can be rich in thymoma, type B1,
epithelial cell proliferation should be found in the lymphoid
component. By immunohistochemistry, the present case
did not show any epithelial proliferation in the thymus,
ruling out thymoma. Furthermore, the surgical findings of

the mediastinal mass, such as adhesion to the surrounding
tissues and invasion to the phrenic nerve, also highly suggested a malignant and aggressive process, though thymoma
at higher clinical stage can be locally aggressive. Unfortunately, no further suspicion for malignancy was raised
until the patient developed a widely spread disease and B
symptoms in a year after initial surgery.
It is also noted in the present case that few histiocytes
were identified in the thymic lymphoma, whereas abundant
histiocytes were present in the nodal lymphoma. It is not clear
why there was such significant difference in the amount of
histiocytes between the patient’s thymic mass and involved
lymph nodes. Although studies have suggested that THRLBCL cases with less (≤70%) or more (>70%) T cell infiltration
significantly differ in clinical presentation or outcome [12],
it is unknown if the amount of histiocytes is relevant to the
disease progression and prognosis.
The present patient’s development of lymphoma might be
related to her long-standing history of SS. SS is a chronic
autoimmune epithelitis characterized by lymphocytic infiltration of exocrine glands together with polyclonal B cell
activation [2, 3]. The clinical spectrum of SS extends from
autoimmune exocrinopathy to a systemic disease affecting
the musculoskeletal, pulmonary, renal, gastrointestinal, and
vascular systems. Before the identification of the mediastinal
mass, the present patient’s SS had involved multiple systems
and developed cryoglobulin, leukocytoclastic vasculitis, and
mononeuritis multiplex. As a well-known risk factor for
lymphoma, SS is associated with a risk of NHL 44 times
greater than in a normal population [4]. Compared to other
systemic autoimmune diseases, SS is associated with the highest risk for NHL development, with a standardized incidence
rate of 18.9 (95% CI 9.4–37.9) [13]. Although the precise
mechanisms have not been elucidated, chronic stimulation
by exoantigen or autoantigen may play an important role
in the development of NHL in SS patients, by driving the
proliferation of specific B cells and increasing the frequency
of their transformation. Additional oncogenic events, such as
inactivation of tumor suppression genes and/or activation of
protooncogenes, may also be required before clones become
malignant and are capable of widespread dissemination and
growth [2]. The prevalence of NHL in SS is about 5% and
the median time from SS diagnosis to lymphoma diagnosis is
7.5 years [4]. Various subtypes of NHL have been described
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in SS. MALT lymphoma has been identified as the most
common NHL in SS patients [14] and thymic MALT lymphoma has been reported in patients with SS [15]. Compared
to MALT lymphoma in general, thymic MALT lymphoma
has some distinct features: predilection for East Asians
(especially from Japan), strong association with autoimmune
diseases especially with SS syndrome, cyst formation, and
IgA expression of the tumor cells [15]. Histologically, thymic
MALT lymphoma is characterized by centrocyte-like cells
and infiltrated Hassall’s corpuscles, forming lymphoepithelial
lesions [16, 17]. In addition to MALT lymphoma, other B cell
lymphomas are also associated with SS. However, THRLBCL
is extremely rare in patients with SS. So far, there is only one
reported case of THRLBCL (in parotid gland) in SS patients
[5].
In the present case, both follicular lymphoid hyperplasia
in the thymus and prominent atypical lymphoid hyperplasia
in multiple lymph nodes were noted. Reactive lymphoid
hyperplasia is a benign nodular lesion, histopathologically
characterized by marked proliferation of nonneoplastic, polyclonal lymphocytes forming follicles with an active germinal
center [18, 19]. Follicular hyperplasia or atypical lymphoid
hyperplasia is not uncommon in SS [20]. Whether the
lymphoid hyperplasia in the present patient provided fertile
ground for her lymphoma remains a speculation.
THRLBCL is an aggressive lymphoma. Patients often
present with an intermediate to high risk International
Prognostic Index (IPI) score and the 3-year overall survival
is only 46% [1, 21]. The poor outcome is probably related to
the advanced stage of disease at diagnosis. The disease is often
disseminated at the time of diagnosis because 57% to 82% of
patients present with Ann Arbor stage-III and stage-IV disease [21]. However, when patients are well matched according
to the IPI and the treatment is adapted to the disease risk,
THRLBCL and conventional DLBCL have similar outcomes
(response and survival) after chemotherapy. Therefore, after
scoring patients according to their IPI, therapy should be
similar in THRLBCL and conventional DLBCL patients [21].
The poor results observed in some patients with THRLBCL
could be explained by an inappropriate initial therapy rather
than a more aggressive clinical pattern [22]. Cases with
extension to adjacent organs or thoracic structures (as seen in
the present patient), pleural or pericardial effusion, or poor
performance status have been associated with unfavorable
clinical outcome. On recurrence, the number of atypical
cells may increase, resulting in a picture of DLBCL, which
indicates a bad outcome [23].
In conclusion, we present the first case of THRLBCL
in the thymus. This patient had a long history of SS and
lymphoid hyperplasia was also identified in the thymic mass
and lymph nodes. In the thymus, the lymphocyte-rich
background of THRLBCL can easily mimic lymphocyte
predominant thymoma. Recognition of thymic THRLBCL is
important for appropriate clinical management. Inappropriate initial therapy may result in worse outcome. The poor
results in some of the cases described in literature may have
been related to inappropriate initial diagnosis and therapy
rather than being due to an inherently more aggressive
biological behavior. Delayed diagnosis and inadequate initial
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therapy may comprise the potential for salvage and long-term
survival. Physicians should be careful not to overlook this
disease when a patient with a thymic tumor is suffering from
autoimmune diseases, especially SS.
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